Harvest Fund Management Co. Ltd Purchases New Position in CymaBay Therapeutics, Inc. (NASDAQ:CBAY)

Harvest Fund Management Co. Ltd purchased a new stake in CymaBay Therapeutics, Inc. (NASDAQ:CBAY) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,076 shares of the biopharmaceutical company’s stock, valued at approximately $26,000.

A number of other institutional investors and hedge funds have also bought and sold shares of CBAY. SG Americas Securities LLC acquired a new position in CymaBay Therapeutics in the 3rd quarter valued at about $230,000. Strategic Blueprint LLC grew its position in shares of CymaBay Therapeutics by 6.3% during the 3rd quarter. Strategic Blueprint LLC now owns 16,800 shares of the biopharmaceutical company’s stock worth $250,000 after purchasing an additional 1,000 shares in the last quarter. Raymond James & Associates grew its position in shares of CymaBay Therapeutics by 14.7% during the 3rd quarter. Raymond James & Associates now owns 39,515 shares of the biopharmaceutical company’s stock worth $589,000 after purchasing an additional 5,050 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its position in shares of CymaBay Therapeutics by 3.5% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 101,329 shares of the biopharmaceutical company’s stock worth $1,511,000 after purchasing an additional 3,434 shares in the last quarter. Finally, Emerald Advisers LLC acquired a new position in shares of CymaBay Therapeutics during the 3rd quarter worth approximately $14,668,000. Institutional investors and hedge funds own 95.03% of the company’s stock.

CymaBay Therapeutics Price Performance

Shares of NASDAQ:CBAY opened at $32.48 on Friday. The company has a market cap of $3.73 billion, a price-to-earnings ratio of -33.48 and a beta of 0.32. The firm has a 50 day simple moving average of $32.40 and a 200 day simple moving average of $24.80. CymaBay Therapeutics, Inc. has a one year low of $7.26 and a one year high of $32.50.

CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.04). The firm had revenue of $0.06 million for the quarter, compared to analysts’ expectations of $0.42 million. As a group, analysts expect that CymaBay Therapeutics, Inc. will post -1.38 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on CBAY shares. SVB Leerink restated a “market perform” rating and set a $32.50 target price on shares of CymaBay Therapeutics in a research report on Tuesday, February 20th. Cantor Fitzgerald lowered shares of CymaBay Therapeutics from an “overweight” rating to a “neutral” rating and set a $32.50 target price on the stock. in a research report on Tuesday, February 13th. Raymond James lowered shares of CymaBay Therapeutics from an “outperform” rating to a “market perform” rating and set a $32.50 price target on the stock. in a research report on Tuesday, February 13th. William Blair lowered shares of CymaBay Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, February 12th. Finally, UBS Group reiterated a “neutral” rating and set a $32.50 price target (up previously from $25.00) on shares of CymaBay Therapeutics in a research report on Wednesday, February 14th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $28.65.

Insiders Place Their Bets

In other CymaBay Therapeutics news, Director Janet Dorling sold 6,000 shares of the firm’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $31.97, for a total value of $191,820.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 7.00% of the company’s stock.

CymaBay Therapeutics Profile

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC).